Literature DB >> 32444437

Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD.

Haval Balata1,2, Jonathan Harvey3, Phil V Barber3, Denis Colligan4, Rebecca Duerden3, Peter Elton5, Matthew Evison3, Melanie Greaves3, John Howells6, Klaus Irion7, Devinda Karunaratne7, Stuart Mellor8, Tom Newton8, Richard Sawyer3, Anna Sharman3, Elaine Smith3, Ben Taylor9, Sarah Taylor4, Janet Tonge4, Anna Walsham10, James Whittaker11, Joergen Vestbo2, Richard Booton3,2, Phil A Crosbie3,12.   

Abstract

BACKGROUND: COPD is a major cause of morbidity and mortality in populations eligible for lung cancer screening. We investigated the role of spirometry in a community-based lung cancer screening programme.
METHODS: Ever smokers, age 55-74, resident in three deprived areas of Manchester were invited to a 'Lung Health Check' (LHC) based in convenient community locations. Spirometry was incorporated into the LHCs alongside lung cancer risk estimation (Prostate, Lung, Colorectal and Ovarian Study Risk Prediction Model, 2012 version (PLCOM2012)), symptom assessment and smoking cessation advice. Those at high risk of lung cancer (PLCOM2012 ≥1.51%) were eligible for annual low-dose CT screening over two screening rounds. Airflow obstruction was defined as FEV1/FVC<0.7. Primary care databases were searched for any prior diagnosis of COPD.
RESULTS: 99.4% (n=2525) of LHC attendees successfully performed spirometry; mean age was 64.1±5.5, 51% were women, 35% were current smokers. 37.4% (n=944) had airflow obstruction of which 49.7% (n=469) had no previous diagnosis of COPD. 53.3% of those without a prior diagnosis were symptomatic (n=250/469). After multivariate analysis, the detection of airflow obstruction without a prior COPD diagnosis was associated with male sex (adjOR 1.84, 95% CI 1.37 to 2.47; p<0.0001), younger age (p=0.015), lower smoking duration (p<0.0001), fewer cigarettes per day (p=0.035), higher FEV1/FVC ratio (<0.0001) and being asymptomatic (adjOR 4.19, 95% CI 2.95 to 5.95; p<0.0001). The likelihood of screen detected lung cancer was significantly greater in those with evidence of airflow obstruction who had a previous diagnosis of COPD (adjOR 2.80, 95% CI 1.60 to 8.42; p=0.002).
CONCLUSIONS: Incorporating spirometry into a community-based targeted lung cancer screening programme is feasible and identifies a significant number of individuals with airflow obstruction who do not have a prior diagnosis of COPD. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  COPD epidemiology; lung cancer

Year:  2020        PMID: 32444437     DOI: 10.1136/thoraxjnl-2019-213584

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  5 in total

1.  Making the case for spirometry as part of the perioperative multidisciplinary team assessment.

Authors:  Thomas Chambers; Mevan Gooneratne; Richa Singh; Ching Pang; Gayle McDonnell; William Ricketts
Journal:  Future Healthc J       Date:  2022-03

2.  Feasibility and acceptability of a community pharmacy referral service for suspected lung cancer symptoms.

Authors:  Daniella Holland-Hart; Grace M McCutchan; Harriet Dorothy Quinn-Scoggins; Kate Brain; Lucy Hill; Savita Shanbag; Michael Abel; Kelly White; Angela Evans; Sarah Rees; Sarah Bowen; Rachel Gemine; Gareth Collier
Journal:  BMJ Open Respir Res       Date:  2021-08

3.  Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

Authors:  Hitomi Ajimizu; Hiroaki Ozasa; Susumu Sato; Tomoko Funazo; Yuichi Sakamori; Takashi Nomizo; Kiyomitsu Kuninaga; Tatsuya Ogimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Takahiro Tsuji; Hironori Yoshida; Ryo Itotani; Kentaro Ueno; Young Hak Kim; Shigeo Muro; Toyohiro Hirai
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

4.  Impact of Chronic Obstructive Pulmonary Disease on the Mortality of Patients with Small Cell Lung Cancer.

Authors:  Kuang-Ming Liao; Chao-Ming Hung; Chin-Chung Shu; Ho-Sheng Lee; Yu-Feng Wei
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-12-01

5.  Lung function impairment in the German Lung Cancer Screening Intervention Study (LUSI): prevalence, symptoms, and associations with lung cancer risk, tumor histology and all-cause mortality.

Authors:  Rudolf Kaaks; Evangelia Christodoulou; Erna Motsch; Verena Katzke; Mark O Wielpütz; Hans-Ulrich Kauczor; Claus Peter Heussel; Monika Eichinger; Stefan Delorme
Journal:  Transl Lung Cancer Res       Date:  2022-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.